Understand the source comparison
GHRP-6 Acetate for Women: Peptide Comparison
This table focuses specifically on how GHRP-6 Acetate performs in female-specific research contexts compared to the most commonly studied alternatives. GH Response in Female Subjects 8–12 ng/mL peak (40% higher than male subjects at same dose) 5–8 ng/mL peak (
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table focuses specifically on how GHRP-6 Acetate performs in female-specific research contexts compared to the most commonly studied alternatives.
- GH Response in Female Subjects
- 8–12 ng/mL peak (40% higher than male subjects at same dose)
- 5–8 ng/mL peak (sex differences minimal)
- 10–14 ng/mL peak (30% higher in women)
- GHRP-2 produces highest female GH response but with appetite increase; Ipamorelin best for appetite-neutral studies
- Appetite Effect in Women
- Significant—30–50% increase in hunger signaling via ghrelin pathway
- Minimal to none
- Moderate—15–25% increase
- GHRP-6's appetite stimulation is more pronounced in female subjects; consider this in calorie-controlled research
- Hormonal Cycle Interaction
- High—estrogen potentiates response by 40–60% during follicular phase
- Low—consistent response across cycle
- Moderate—20–30% variation with estrogen
- GHRP-6 benefits most from cycle-aware dosing; Ipamorelin provides stable response regardless of cycle phase
- Prolactin/Cortisol Elevation
- Minimal (<5% increase at ≤200 mcg doses)
- None at standard research doses
- Low to moderate (10–15% at 300 mcg)
- All three are safe from endocrine disruption at typical research doses; Ipamorelin cleanest profile
- Optimal Female Research Dose
- 75–150 mcg (lower than male dose due to higher sensitivity)
- 100–200 mcg (same as male dose)
- 75–150 mcg (lower than male dose)
- Female-specific protocols should reduce GHRP-6 and GHRP-2 doses by 25–30% compared to male models